Kidney; Complications, Allograft, Transplantation Infection
Conditions
Keywords
Bcells, kidney allograft dysfunction, antibody mediated rejection
Brief summary
The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.
Detailed description
The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune responses after kidney transplantation. This study aims to address two major challenges in kidney transplantation: 1. to guide physicians when immunosuppressive drugs are weaned, and 2. to identify patients who are at risk or in the process of developing antibody-mediated rejection. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.
Interventions
DRUGImmunosuppressive Agents
standard of care for patients post-transplant
Sponsors
Loma Linda University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to understand and willingness to sign the written informed consent form (ICF). For pediatric patients, a parent or legal guardian must sign ICF * Either a Kidney or Liver transplant patient: 1) on the waitlist or 2) transplanted * Healthy volunteer samples collected to use as the control group for statistical validity
Exclusion criteria
* Inability to make all of the required long-term post-transplant visits. * Females who are pregnant or nursing a child * Liver patients with hepatitis C virus
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood collection prior to and after kidney transplantation | 1,3,6,12,18,24,36,48, and 60 months | Blood will be collected from kidney transplant patients prior to and after their transplant (1-, 3-, 6-, 12-, 18-, 24-, 36-, 48-, and 60- months post-transplant). We will try to better understand the role of specific B-cells after kidney transplant by using enzyme-linked immunosorbent assay (ELISA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| B cell count | Up to 60 months | For each patient, we will be measuring the frequency of cells from each B cell subset within the total peripheral blood mononuclear cells (PBMNCs) by MACSQuant cell counts. The distribution of B cells subsets within the total B cell pool will also be determined. Mean Fluorescence Intensity (MFI) of activation markers (CD86 and CD69) on B cells will also be compared across the samples. |
Countries
United States
Outcome results
None listed